Nong Lin, Zheng Yalin, Li Xin, Li Dong, Liang Li, Wang Wei, Li Ting
Department of Pathology, Peking University First Hospital, Beijing 100034, China.
Department of Pathology, Peking University First Hospital, Beijing 100034, China.
Pathol Res Pract. 2022 May;233:153860. doi: 10.1016/j.prp.2022.153860. Epub 2022 Mar 28.
To investigate the clinical implications of the PRDM1 deletion and PRDM1 protein expression in Chinese diffuse large B cell lymphoma (DLBCL).
Tumor samples of 199 patients with DLBCL were obtained from the Department of Pathology of Peking University First Hospital between 2008 and 2015. The PRDM1 expression was detected by immunohistochemistry (IHC) in all samples. Among them, the PRDM1 deletion was detected in 60 samples by fluorescence in situ hybridization (FISH). The correlations between PRDM1 protein expression and PRDM1 molecular status and clinicopathological features were analyzed.
Immunohistochemically, 58 (29.1%) patients were classified as the germinal center B-cell (GCB) subtype, and 141 (70.9%) patients were non-GCB subtype. PRDM1 protein was strongly expressed in 15 (7.5%) patients, weakly expressed in 67 (33.7%) patients, and negative in 117 (26.6%) patients. Heterozygous and homozygous PRDM1 deletions were observed in 28.3% (17/60) and 8.3% (5/60) of cases, respectively. The PRDM1 deletion was not significantly correlated with PRDM1 protein expression. Neither the PRDM1 protein expression nor the PRDM1 deletion was significantly associated with most clinicopathological features, including their immunophenotypes according to the Han's algorithm. However, Kaplan-Meier survival analysis showed that heterozygous and/or homozygous PRDM1 deletion but not PRDM1 expression was a poor prognostic factor in the non-GCB group. In addition, there was a positive correlation between PRDM1 and c-Myc expression.
Our results suggested that homozygous or heterozygous PRDM1 deletion is a poor prognostic factor for non-GCB DLBCL.
探讨PRDM1缺失及PRDM1蛋白表达在中国弥漫性大B细胞淋巴瘤（DLBCL）中的临床意义。
2008年至2015年间从北京大学第一医院病理科获取199例DLBCL患者的肿瘤样本。采用免疫组织化学（IHC）检测所有样本中PRDM1的表达。其中，60个样本通过荧光原位杂交（FISH）检测PRDM1缺失情况。分析PRDM1蛋白表达与PRDM1分子状态及临床病理特征之间的相关性。
免疫组织化学检测显示，58例（29.1%）患者为生发中心B细胞（GCB）亚型，141例（70.9%）患者为非GCB亚型。PRDM1蛋白在15例（7.5%）患者中强表达，在67例（33.7%）患者中弱表达，在117例（26.6%）患者中阴性表达。分别在28.3%（17/60）和8.3%（5/60）的病例中观察到PRDM1杂合缺失和纯合缺失。PRDM1缺失与PRDM1蛋白表达无显著相关性。PRDM1蛋白表达和PRDM1缺失均与大多数临床病理特征无显著关联，包括根据汉斯算法的免疫表型。然而，Kaplan-Meier生存分析显示，PRDM1杂合和/或纯合缺失而非PRDM1表达是非GCB组的不良预后因素。此外，PRDM1与c-Myc表达呈正相关。
我们的结果表明，PRDM1纯合或杂合缺失是非GCB DLBCL的不良预后因素。
